Mefloquine plus cotrimoxazole leads to higher AEs: vomiting compared with cotrimoxazole (high certainty).
Mefloquine plus cotrimoxazole leads to higher AEs: dizziness compared with cotrimoxazole (high certainty).
Mefloquine leads to lower maternal peripheral parasitaemia at delivery compared with sulfadoxine‐pyrimethamine (high certainty).
Mefloquine showed no clear difference in placental malaria compared with sulfadoxine‐pyrimethamine (low certainty).
Mefloquine probably leads to lower maternal anaemia at delivery compared with sulfadoxine‐pyrimethamine (moderate certainty).
Mefloquine showed no clear difference in low birth weight compared with sulfadoxine‐pyrimethamine (high certainty).
Mefloquine showed no clear difference in stillbirths and abortions compared with sulfadoxine‐pyrimethamine (moderate certainty).
Mefloquine leads to higher AEs: vomiting compared with sulfadoxine‐pyrimethamine (high certainty).
Mefloquine probably leads to higher AEs: dizziness compared with sulfadoxine‐pyrimethamine (moderate certainty).
Mefloquine plus cotrimoxazole showed no clear difference in clinical malaria episodes during pregnancy compared with cotrimoxazole (high certainty).
Smectite may leads to higher clinical resolution at day 3 compared with control (low certainty).
Smectite showed no clear difference in need for hospitalization compared with control (low certainty).
Smectite showed no clear difference in need for intravenous access for rehydration compared with control (moderate certainty).
Smectite showed no clear difference in adverse events – constipation compared with control (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether topical repellents changes clinical malaria: P. falciparum compared with placebo or no treatment (very low certainty).